Shedding of bevacizumab in tumour cells-derived extracellular vesicles as a new therapeutic escape mechanism in glioblastoma

Glioblastoma (GBM) is the most aggressive type of primary brain tumours. Anti-angiogenic therapies (AAT), such as bevacizumab, have been developed to target the tumour blood supply. However, GBM presents mechanisms of escape from AAT activity, including a speculated direct effect of AAT on GBM cells...

Descripción completa

Detalles Bibliográficos
Autores principales: Simon, Thomas, Pinioti, Sotiria, Schellenberger, Pascale, Rajeeve, Vinothini, Wendler, Franz, Cutillas, Pedro R., King, Alice, Stebbing, Justin, Giamas, Georgios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6117885/
https://www.ncbi.nlm.nih.gov/pubmed/30165850
http://dx.doi.org/10.1186/s12943-018-0878-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6117885/
https://www.ncbi.nlm.nih.gov/pubmed/30165850
http://dx.doi.org/10.1186/s12943-018-0878-x

Ejemplares similares